Basic research for overcoming of target therapy resistance in anaplastic thyroid carcinoma with BRAF V600E

2022 Fiscal Year Final Research Report

• Project/Area Number: 20K16379
• Research Category: Grant-in-Aid for Early-Career Scientists
• Allocation Type: Multi-year Fund
• Review Section: Basic Section 50020:Tumor diagnostics and therapeutics-related
• Research Institution: Kanazawa University
• Principal Investigator: Nishiyama Akihiro 金沢大学, がん進展制御研究所, 助教 (80770172)
• Project Period (FY): 2020-04-01 – 2023-03-31
• Keywords: 甲状腺未分化がん / BRAF V600E

Outline of Final Research Achievements

We did gene ontology analysis for subcutaneous tumors made from anaplastic thyroid cancer (ATC) cell line with BRAF V600E. Target therapy resistant tumor had more mutations related with extracellular space、cytokine activity or integral component of plasma membrane than subcutaneous tumor without therapy. Since the condition of ATC became worse and then we saw the worsened inflammatory reaction, we will focus on the gene alteration on cytokine activity and keep going on analyses.

Free Research Field

分子標的薬耐性

Academic Significance and Societal Importance of the Research Achievements

甲状腺未分化がんの病勢悪化時には、炎症反応が悪化することが多い。
in vivoにて薬剤耐性を誘導した際にも、耐性腫瘤はcytokine activity関連の遺伝子において有意に変化を認め、実際の臨床での経過に矛盾しない結果となった。
これらに、着目して病勢増悪を遅らせるための治療法開発に結び付けたい。